How long do exosomes last depends on which of two questions is being asked. In the vial it is a storage question: for the exosome material ExaVeyra supplies, ExaVeyra’s handling instructions set -20°C for long-term storage, then 4°C once a vial is thawed with use within 24 hours and no refreezing, and each lot carries its own expiry.
On the skin, the most reliable answer is the follow-up interval a study measured. The controlled facial studies cited here assessed participants at visits between 4 weeks and 6 months [4, 5, 6, 7, 8], which describes how long researchers looked and sets no expectation for any individual.
Most answers online blend those two meanings, so this guide takes them one at a time: shelf life, storage and handling first, then the session schedules and assessment visits of the published studies, then what the evidence does not yet show and what a practice can record.
Regulatory position
The FDA stated in its 2019 public safety notification that there are currently no FDA-approved exosome products [16]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats. Nothing in this guide promises a result or a duration, and clinical use, patient selection and session planning are practitioner decisions this article does not make.
Separating shelf life from the duration of a measured result
The first question is about the material: how long a vial keeps its quality before use, which depends on temperature, formulation and handling. The second is about the person: how long a change measured after a session persists, which only a study with a long enough follow-up can describe.
The two answers come from different sources and are best kept apart. Shelf life comes from the manufacturer and the lot record, while follow-up comes from the published studies, each of which stopped measuring at a set visit.
| Question | What governs the answer | Where the answer comes from | What it cannot tell you |
|---|---|---|---|
| How long does a vial keep? | Storage temperature, formulation, freeze-thaw history | The handling instructions and the lot expiry | Anything about outcomes on the skin |
| How long does a thawed vial keep? | Time at 4°C after thawing, diluent, handling | ExaVeyra’s handling instructions: 4°C and use within 24 hours, with the thaw time recorded on the vial | Anything about outcomes on the skin |
| How long before a change is measured? | Session spacing and visit timing in each study | Published studies and their assessment visits | What one person will experience |
| How long does a measured change persist? | Length of follow-up after the last session | The final visit in each study, from 6 weeks to 6 months here | Anything after the last visit a study reported |
Understanding exosomes shelf life as a property of each lot
Exosomes shelf life is set by the expiry assigned to each lot and by the storage conditions the manufacturer specifies, because vesicle stability depends on formulation, buffer and container as much as on temperature. ExaVeyra exosome material ships frozen from the manufacturing facility in all formats, including the skincare serum, and every vial carries its lot number.
A certificate of analysis is generated for every lot and is available on request, together with the characterization panel and cold-chain records. Every ExaVeyra certificate reports serological testing for pathogens, so the lot record answers the material question in writing, and miRNA characterization data is also available on request.
The wider market is less consistent. Knauer and colleagues surveyed 20 commercial cosmetic exosome products in a 2026 scoping review and reported that they carried minimal information on exosome isolation, processing or shelf life [3].
Laboratory studies show why shelf life belongs to the specific product. Gordiienko and colleagues reported in 2026 that stromal cell vesicles diluted in Hank’s solution kept stable particle and protein concentrations for at least 14 days at +4°C to +6°C and for at least 6 months at -20°C, with characteristics preserved for at least 10 months at -80°C; six of the eight authors were employed by a medical company [13].
Görgens and colleagues followed vesicle preparations for up to 2 years in 2022 and reported that the storage buffer strongly affected recovery at every temperature tested. Plain phosphate-buffered saline reduced vesicle recovery starting within days, while saline supplemented with human albumin and trehalose improved short-term and long-term preservation at -80°C and stability through several freeze-thaw cycles [14].
Holding material frozen and limiting thaws protects vesicle integrity
For ExaVeyra exosome material, ExaVeyra’s handling instructions call for -20°C for long-term storage. Once a vial is thawed it is kept at 4°C, used within 24 hours and never refrozen, and the thaw date and time are written on the vial.
Freeze-thaw cycles explain why a thawed vial is held cold rather than refrozen. Gelibter and colleagues reported in 2022 that vesicle numbers fell after the first freeze-thaw cycle and particle size rose with each further cycle [15], and Ahmadian and colleagues reported across 50 studies in a 2024 systematic review that repeated freeze-thaw cycles lowered particle concentration and RNA content, impaired bioactivity, and increased vesicle size and aggregation [12].
The MISEV2023 guideline from the International Society for Extracellular Vesicles asks that freeze-thaw cycles be kept to a minimum and that storage temperature, storage time and the number of cycles be reported [11]. In a practice that becomes one habit: thaw a vial once, hold it at 4°C, and record the time.
Reading the follow-up intervals the published studies measured
On the skin side, the useful question is when each study looked. The controlled facial studies below repeated sessions at set intervals and then assessed participants at fixed visits, and every figure in the table is an interval the authors reported.
| Study | Design and size | Procedure step | Session spacing | Assessment visits reported |
|---|---|---|---|---|
| Park GH 2023 [4] | Randomized split-face, n = 28, saline on the control side | Microneedling | 3 sessions, 3 weeks apart | Final visit 6 weeks after the last session, 12 weeks overall |
| Kwon 2020 [5] | Double-blind randomized split-face, n = 25, control gel | Fractional CO2 laser | 3 sessions, 3 weeks apart | Post-session visits and a final visit 6 weeks after the last session |
| Estupiñan 2025 [6] | Investigator-blinded split-face, n = 15, PRP on the other side | RF microneedling | 3 sessions, 4 weeks apart | 3 and 6 months after the sessions, with biopsies in 10 participants |
| Yen 2026 [7] | Randomized split-face, unblinded, n = 60, RF microneedling alone on the control side | RF microneedling | Not given in the abstract | Baseline, week 4 and week 12 |
| Huang 2026 [8] | Split-face pilot, random side assignment, n = 6 | Needling RF | Not given in the abstract | 1, 3 and 6 months |
| Proffer 2022 [9] | Single-arm, non-randomized, no comparison group | None; topical home regimen | Standardized home skin care regimen | Baseline and 6 weeks |
Read that way, the table answers a narrower and more dependable question. The longest assessment in these studies came 6 months after the sessions, in Estupiñan and colleagues’ 15-person trial and Huang and colleagues’ 6-person pilot [6, 8], and none of them reported what happened after their final visit.
The study populations also differed. Kwon and colleagues enrolled adults with atrophic acne scars [5], Estupiñan and colleagues enrolled adults with mild to moderate photoaging [6], and the vesicle sources ranged from adipose stem cells to platelets and a rose stem cell formulation [4, 8, 9].
Interpreting how long it takes for exosomes to work in a study design
A search for how long it takes for exosomes to work is a question about when a change was first measured. Kwon and colleagues reported that the difference between the exosome and control sides after fractional CO2 was not significant at the first post-session visit and became significant at the second [5], and Huang and colleagues reported greater wrinkle reduction on the vesicle side at 1 and 3 months [8].
Yen and colleagues set their primary endpoint at week 12 and reported a paired wrinkle-score difference of 3.32 points favoring the vesicle side, while noting that the unblinded design and 12-week follow-up require cautious interpretation [7]. Proffer and colleagues assessed a topical platelet-derived serum at baseline and 6 weeks in a single-arm study funded by the product maker [9].
A first significant visit marks when a study first looked closely enough to detect a group difference, and a different visit schedule might have placed it earlier or later. None of these designs can say when a change begins for a given person.
Reading how long exosome microneedling lasts as measured intervals
The question of how long exosome microneedling lasts has two short answers in the literature, one in hours and one in months. Gupta and colleagues reported in 2011 that uncovered microneedle sites in human volunteers recovered their barrier within 2 hours [10], and studies such as Huang and colleagues’ applied the vesicle material immediately after the needling step [8].
In months, Park and colleagues’ microneedling study ended 6 weeks after the third session, where the authors reported a higher global aesthetic score on the exosome side and no serious adverse events [4]. Estupiñan and colleagues followed RF microneedling participants to 6 months and reported equal improvement on the exosome and PRP sides, with increased collagen I and glycosaminoglycans on histology in both arms [6].
Huang and colleagues reported sustained remodeling at 6 months on the vesicle side and rebound worsening on the side that received needling RF alone, in a preliminary study of 6 people [8]. Those are the longest intervals the located studies measured, so any statement that a result lasts a year or more has no support among the controlled studies cited here.
The device side has its own limits. The FDA states that microneedling devices are not approved for delivering cosmetics, topical medications, drugs or blood products into the skin, and that the risks of combining the devices with other products are not known [17].
Recognizing what the evidence does not yet show
- None of the controlled studies cited here followed participants beyond 6 months after their sessions, so these studies give no estimate of how long a measured change persists after that point [6, 8]
- Gaebe and colleagues rated the certainty of evidence across 16 facial vesicle studies with 503 participants as low or very low in 2026, and concluded that short follow-up and inconsistent outcome assessment preclude definitive conclusions [1]
- Stack and colleagues reported a pooled 20.2 percent facial wrinkle reduction in a 2026 meta-analysis while noting heterogeneity and nonstandardized protocols, and the pooled figure carries no timeline of its own [2]
- The studies used different vesicle sources, procedure steps and visit schedules, so their intervals cannot be combined into one expected course
- Several studies were small or industry-supported: Huang and colleagues enrolled 6 people, Estupiñan and colleagues received a research grant from an exosome product maker, and Proffer and colleagues were funded by the product maker [6, 8, 9]
- Repeat or maintenance schedules after a study ended were outside the designs cited here
- The storage studies used research preparations, and none located for this guide tested commercial topical exosome products under clinic conditions across their full shelf life [12, 13, 14, 15]
Those gaps are a reason to read every timeline as a feature of a study design. They also make a practice’s own records valuable, because a well-kept file is the closest thing to follow-up data a single practice can hold.
Documenting shelf life and follow-up in the practice file
A practice that records the same fields for the vial and for the visit schedule can answer either version of the question from its own file. The fields below follow the studies and guidance cited above.
- The lot number and expiry of every vial, matched to the certificate of analysis and characterization panel requested from the supplier
- The arrival date and time, whether the shipment arrived frozen, and the freezer used with its temperature reading
- The thaw date and time, the use-by time (24 hours after thawing for ExaVeyra material), and the time of use
- The procedure step and device, the session dates and the spacing between them
- Photographs and measurements taken at the same visit points each time, so later visits compare like with like
- Any adverse event, recorded with the lot number
Questions to ask a supplier
- What expiry does each lot carry, and what storage temperature does the manufacturer specify before and after thawing?
- Is there a use-by window after thawing, and where is it written?
- Can the practice request the certificate of analysis, characterization panel and cold-chain records for a specific lot?
- Which published studies used comparable material, and what follow-up did those studies measure?
Separating the vial from the visit schedule makes both answers clearer for practices and the patients they advise. ExaVeyra exosome material ships frozen from the manufacturing facility, with each lot’s certificate of analysis, characterization panel and cold-chain records available on request, and the cold-chain validation page sets out how the material stays frozen from dispatch to the practice door.
As longer and better controlled studies report, practices that keep careful records will be well placed to read them against their own experience. Anyone can ask the scientific team a question or apply without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing, so a practice that wants to carry exosome material can apply for a verified account today.
Aviso Educativo: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Referencias
- 1.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: the authors rated certainty low or very low and concluded that methodological limitations, inconsistent outcome assessment and short follow-up preclude definitive conclusions, the central limit on any duration claim. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
- 2.Stack ER, Spongberg C, Braud SC, Stanton WN, Elway M. Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials. Aesthet Surg J. 2026;46(12 Suppl 2):S13-S25. PMID 41800726. doi:10.1093/asj/sjaf178Systematic review and random-effects meta-analysis, search of 2 February 2025; 39 human studies (26 skin, 13 hair). Carries in this article: the reported pooled facial wrinkle reduction of 20.2 percent, which the authors qualified for heterogeneity and nonstandardized protocols and which carries no timeline of its own. Disclosure: published in an Aesthetic Surgery Journal supplement on exosomes; the PubMed record carries no funding or COI statement.
- 3.Knauer G, Chang A, Gupta A, Brownstone N, Mejia N, Bauman S, et al. Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review. Aesthet Surg J. 2026;46(11):NP148-NP157. PMID 42411735. doi:10.1093/asj/sjag141Scoping review with a librarian-reviewed search (2,394 records screened; 18 human studies) plus a survey of the first 20 commercial cosmetic exosome products found by an online shopping search. Carries in this article: the authors reported that the commercial products carried minimal information on exosome isolation, processing or shelf life. Disclosure: academic authors (Temple University, Mount Sinai); no COI statement in the PubMed record.
- 4.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face study; three microneedling sessions 3 weeks apart, saline on the control side, follow-up 6 weeks after the last session; adults in Korea; n = 28. Carries in this article: the microneedling session spacing and the final visit 6 weeks after the third session, where the authors reported a higher global aesthetic score on the exosome side and no serious adverse events. Disclosure: the PubMed record lists government research grants and no COI statement.
- 5.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized, split-face trial; three fractional CO2 sessions 3 weeks apart, follow-up 6 weeks after the last; adults with atrophic acne scars as the study population (Korea); n = 25. Carries in this article: the full text reports that the between-side difference was not significant at the first post-session visit and became significant at the second, the earliest-difference example. Disclosure: the exosome and control solutions were manufactured, purified and provided by the exosome manufacturer (acknowledgements); the authors declared no conflicts of interest.
- 6.Estupiñan B, Ly K, Goldberg DJ. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face, Non-Inferiority Trial. J Cosmet Dermatol. 2025;24(5):e70208. PMID 40414798. PMC12104007. doi:10.1111/jocd.70208Investigator-blinded, split-face, non-inferiority trial; three full-face RF microneedling sessions at 4-week intervals, topical exosomes on one half and PRP on the other, photographs at 3 to 6 months and biopsies in the first 10 participants at baseline, 3 and 6 months; adults with mild to moderate photoaging (USA); n = 15. Carries in this article: the 6-month assessment, the longest in the controlled studies cited, where the authors reported equal improvement in both arms. Disclosure: supported in part by a research grant to the investigators' practice from the maker of the exosome products and device (full text); the authors declared no conflicts of interest.
- 7.Yen C, Huang H, Lin C. Radiofrequency Microneedling Combined With Topical Extracellular Vesicle Preparation for Facial Rejuvenation: A Randomized Split-Face Controlled Study. J Craniofac Surg. 2026. Published online ahead of print. PMID 42635327. doi:10.1097/SCS.0000000000013266Randomized split-face controlled study, unblinded, assessed at baseline, week 4 and week 12; adults (Taiwan), mean age 43.6, 83 percent women; n = 60. Carries in this article: the week-12 primary endpoint with a paired wrinkle-score difference of 3.32 points (95% CI 2.55 to 4.08), and the authors' own caution about the unblinded design and 12-week follow-up. Disclosure: the authors reported no conflicts of interest.
- 8.Huang PP, Chih PL, OuYang SY. Preliminary Insights From a Split-Face Study on Skin Quality Changes After Needling Radiofrequency With or Without a Plant-Derived Exosome-Based Formulation Over 6 Months. Aesthet Surg J. 2026;46:S62-S72. PMID 41800727. doi:10.1093/asj/sjaf253Prospective split-face pilot with random side assignment, a rose stem cell-derived vesicle formulation applied immediately after needling RF, assessments at 1, 3 and 6 months; Fitzpatrick III to IV adults; n = 6. Carries in this article: the authors reported greater wrinkle reduction on the vesicle side at 1 and 3 months and sustained remodeling at 6 months, with rebound worsening on the needling RF alone side; preliminary by the authors' own description. Disclosure: published in an Aesthetic Surgery Journal supplement on exosomes; the PubMed record carries no funding or COI statement.
- 9.Proffer SL, Paradise CR, DeGrazia E, Halaas Y, Durairaj KK, Somenek M, et al. Efficacy and Tolerability of Topical Platelet Exosomes for Skin Rejuvenation: Six-Week Results. Aesthet Surg J. 2022;42(10):1185-1193. PMID 35689936. doi:10.1093/asj/sjac149Prospective, single-arm, non-randomized study of a topical platelet-derived exosome serum within a standardized home skin care regimen, no procedure step, evaluated at baseline and 6 weeks with 3D imaging. Carries in this article: a topical-only design with a 6-week assessment and no comparison group. Disclosure: funded by the product maker (Europe PMC grant record); two authors list affiliations with that company.
- 10.Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release. 2011;154(2):148-55. PMID 21640148. PMC3164267. doi:10.1016/j.jconrel.2011.05.021Human in vivo study using electrical impedance across microneedle geometries, with and without occlusion. Carries in this article: the authors reported that unoccluded microneedle sites recovered barrier properties within 2 hours, while occluded sites resealed over 3 to 40 hours depending on needle length, number and cross-section. Disclosure: academic authors (Georgia Institute of Technology); no COI statement in the PubMed record.
- 11.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline, built with ISEV task forces and a survey of about 1,000 researchers. Carries in this article: the guideline asks that freeze-thaw cycles be minimized and that storage temperature, time, thawing method and number of cycles be reported. Disclosure: many consortium authors list EV company affiliations, declared in full in the article.
- 12.Ahmadian S, Jafari N, Tamadon A, Ghaffarzadeh A, Rahbarghazi R, Mahdipour M. Different storage and freezing protocols for extracellular vesicles: a systematic review. Stem Cell Res Ther. 2024;15(1):453. PMID 39593194. PMC11600612. doi:10.1186/s13287-024-04005-7Systematic review of 50 original studies on storage temperature, freezing technique, freeze-thaw cycles and stabilizers. Carries in this article: the authors reported that repeated freeze-thaw cycles lowered particle concentration and RNA content, impaired bioactivity and enlarged and aggregated vesicles. Disclosure: one author was employed by a private research and development company.
- 13.Gordiienko I, Petryk N, Kushka I, Nesenyuk O, Lukasevych M, Novikova S, et al. Storage-associated physicochemical changes in extracellular vesicles derived from human mesenchymal stromal cells. Front Bioeng Biotechnol. 2026;14:1829175. PMID 42597816. PMC13469669. doi:10.3389/fbioe.2026.1829175Laboratory stability study of vesicles from adipose, umbilical cord and dental pulp stromal cells diluted in Hank's solution, measured by NTA, marker ELISA and protein assay. Carries in this article: the authors reported particle and protein concentration stable for at least 14 days at +4°C to +6°C and at least 6 months at -20°C, and characteristics preserved for at least 10 months at -80°C. Disclosure: six of the eight authors were employed by a medical company.
- 14.Görgens A, Corso G, Hagey DW, Jawad Wiklander R, Gustafsson MO, Felldin U, et al. Identification of storage conditions stabilizing extracellular vesicles preparations. J Extracell Vesicles. 2022;11(6):e12238. PMID 35716060. PMC9206228. doi:10.1002/jev2.12238Laboratory stability study of up to 2 years across buffers and temperatures, vesicles from several cell sources. Carries in this article: the authors reported that plain PBS reduced vesicle recovery within days, while PBS with human albumin and trehalose improved preservation at -80°C and stability through several freeze-thaw cycles. Disclosure: three authors are consultants for and hold equity in a vesicle therapeutics company, and four are inventors on a related patent application.
- 15.Gelibter S, Marostica G, Mandelli A, Siciliani S, Podini P, Finardi A, et al. The impact of storage on extracellular vesicles: A systematic study. J Extracell Vesicles. 2022;11(2):e12162. PMID 35102719. PMC8804350. doi:10.1002/jev2.12162Laboratory study of eight storage strategies at -80°C and of freeze-thaw cycles, vesicles from human plasma and mouse microglia culture. Carries in this article: the authors reported that storage lowered concentration and purity over time, that vesicle numbers fell after the first freeze-thaw cycle, and that particle size rose with each further cycle. Disclosure: one author reported advisory and speaking honoraria and research funding from pharmaceutical companies.
- 16.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products.
- 17.U.S. Food and Drug Administration. Microneedling Devices. Content current as of 10/15/2025; verified 9 November 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devicesAgency device information page (CDRH). Carries in this article: the agency states that microneedling devices are not approved for delivery of cosmetics, topical medications, drugs or blood products into the skin, and that the risks of combining the devices with other products are not known.